IP Verse

Dulaglutide For The Treatment Of Chronic Kidney Disease

Patent No. EP3630164 (titled "Dulaglutide For The Treatment Of Chronic Kidney Disease") was filed by ELI Lilly on May 24, 2018. The application was issued on Aug 23, 2023.

Patent Summary

Dulaglutide, a GLP-1R agonist, provides sustained and rapid attenuation of kidney disease progression in patients with stage 2-4 CKD. By targeting the GLP-1 receptor pathway, dulaglutide improves glycemic control, but its therapeutic effects extend beyond glycemic management. The treatment achieves significant renal function preservation, with a median time to renal death of 26 weeks compared to existing therapies, and cardiovascular benefits. Dulaglutide's mechanism of action enables sustained therapeutic effects beyond glycemic control, offering a novel treatment option for patients with CKD stage 2 or worse.

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKMay 23, 2024ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP3630164

ELI LILLY
Application Number
EP18730908A
Filing Date
May 24, 2018
Status
Granted And Under Opposition
Jul 21, 2023
Publication Date
Aug 23, 2023
External Links
Slate, Register , Google Patents